重组组织型纤溶酶原激活剂和尿激酶溶栓治疗超早期脑梗死的疗效观察

目的观察重组组织型纤溶酶原激活剂（rt-PA）与尿激酶（UK）溶栓治疗超早期脑梗死的疗效与安全性。方法将62例超急性脑梗死患者按随机数字表法分为2组,rt-PA组和UK组,每组31例。rt-PA组采用rt-PA静脉溶栓治疗;UK组采用尿激酶静脉溶栓治疗。对2组治疗前及治疗后21 d美国国立卫生院卒中量表（NIHSS）神经功能评分及不良反应进行比较。结果 2组治疗前NIHSS评分比较差异无统计学意义（P〉0.05）;治疗21 d后2组NIHSS分值与治疗前比较明显下降（P〈0.01）,2组NIHSS分值比较差异无统计学意义（P〉0.05）。2组发生出血并发症及病死率比较差异无统计学意义（P〉0.05）。结论 rt-PA与UK早期溶栓治疗超急性期脑梗死疗效和安全性相似。

Intravenous rt-PA and Urokinase Thrombolytic Therapy in Hyperacute Cerebral Infaction

Objective To observe the efficacy and safety of intravenous thrombolysis with recombinant tissue plasminogen activator（rt-PA）and urokinase（UK） in patients with hyperacute cerebral infarction.Methods Sixty-two patients were randomly divided into rt-PA group and UK group,with 31 patients in each group.Comparison of neurological score and adverse reactions between the two groups was carried out before treatment and 21 days after medication by National Institutes of Health stroke scale（NIHSS）.Results There were not significant differences in NIHSS score between the two groups before treatment（P0.05）.NIHSS score in both groups significantly decreased 21 days after thrombolysis,compared with that before treatment（P0.01）,but the differences between the two groups were not significant（P0.05）.There were no significant differences in symptomatic intracerebral hemorrhage rate and mortality rate between the two groups（P0.05）.Conclusion The efficacy and safety of intravenous thrombolysis with rt-PA and UK are similar in patients with hyperacute cerebral infarction.